Private Psychedelic Medicine Company Beckley Psychotech Ltd. has acquired 100% of the clinical-stage life sciences company Eleusis Therapeutics Ltd., giving the former full development and commercial rights to the latter’s assets.

Eleusis CEO Shlomi Raz becomes Beckley’s CBOwhile Eleusis’ R&D team is immediately integrated into the company.

“This is an extremely exciting acquisition for Beckley Psytech and we are pleased to add Eleusis’ innovative products to our portfolio of differentiated clinical assets. Our highly focused pipeline, now bolstered by a Phase 1 ready, next generation short-acting psychedelic will deliver multiple value reversals over the next 18 months. said Beckley’s CEO Cosmo Fielding Mellen.

Feilding added that the former Eleusis team has “extraordinary knowledge and experience” and that Beckley expects his proprietary R&D pipeline to benefit greatly. It is not yet clear whether Eleusis is a scientific founder and renowned psychedelics researcher dr Charles Nichols will join the team.

Beckley’s CEO said the acquisition, coupled with the company’s current liquidity to operate through 2025, will strengthen the company’s position as a leader in the development of psychedelic therapies.

Raz said he’s excited to join the leadership team to develop meaningful, practical, and cost-effective psychedelics solutions and treatments. “Beckley has been a pioneer in psychedelic science for more than two decades and we are excited to be part of that history through this transaction,” he said. “We believe that given our shared commitment to developing psychedelics, Eleusis represents an excellent acquisition for Beckley Psytech to provide drug therapies for patients in dire need of new treatment options.”

The acquisition expands Beckley’s…